Mouse anti-PD1 antibody NAT105 ab52587 is a mouse monoclonal antibody that is used in PD1 western blotting, IHC, immunofluorescence and flow cytometry.
Tried and trusted by researchers since 2007
Anti-PD1 antibody clone NAT105 is cited in over 360 publications
One antibody for all your PD1 staining, use in PD1 western blotting, IHC, immunofluorescence and flow cytometry
IgG1
Mouse
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
IHC-P | Flow Cyt | WB | ICC/IF | IHC-Fr | |
---|---|---|---|---|---|
Human | Tested | Tested | Tested | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 | Notes Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 | Notes We recommend Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) (Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) preadsorbed ab150117) secondary antibody. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/10000 | Notes - |
Select an associated product type
Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed:21276005). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed:21276005). Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity).The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed:28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed:22658127, PubMed:25034862, PubMed:25399552).
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1
Mouse anti-PD1 antibody NAT105 ab52587 is a mouse monoclonal antibody that is used in PD1 western blotting, IHC, immunofluorescence and flow cytometry.
Tried and trusted by researchers since 2007
Anti-PD1 antibody clone NAT105 is cited in over 360 publications
One antibody for all your PD1 staining, use in PD1 western blotting, IHC, immunofluorescence and flow cytometry
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1
IgG1
Mouse
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
NAT105
Affinity purification Protein A
kappa
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Please note that PD-1 is expressed variably in different tissues and that optimisation may be required depending on the tissue used for the experiment.
Western blot protocol advice:
Due to low expression of PD-1, we recommend loading a high amount of sample (100 µg) to detect the band for PD-1. Human tonsil and YT cell line lysates are suitable positive controls.
This product has switched from a hybridoma to recombinant production method on 1st November 2024.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
Programmed cell death protein 1 commonly known as PD-1 or PDCD1 is an immune checkpoint receptor with a molecular mass of approximately 55 kDa. This protein is primarily expressed on the surface of activated T cells B cells and myeloid cells within the immune system. PD-1 plays a mechanical role in modulating immune responses by binding to its ligands PD-L1 and PD-L2 which are expressed on other immune cells and in various other tissues. The engagement of PD-1 with its ligands transmits an inhibitory signal that reduces the proliferation and activity of T cells.
PD-1 serves as a critical immune checkpoint that helps maintain self-tolerance and prevent autoimmunity. PD-1 does not function as part of a multi-protein complex but independently regulates the immune response. By delivering inhibitory signals upon ligand binding PD-1 limits the overactivation of the immune system reducing the likelihood of tissue damage during inflammatory responses. The modulation of T cell activity by PD-1 contributes to a balanced immune system ensuring that the body targets pathogens effectively without harming itself.
PD-1 interacts with key immune-regulatory pathways including the PI3K-Akt and Ras-MAPK pathways. These pathways are important for cell survival growth and metabolism. The interaction of PD-1 with the PI3K-Akt pathway involves proteins such as SHP-2 which dephosphorylates signaling intermediates leading to reduced T cell receptor signaling. PD-1's role in these pathways demonstrates its influence on immune cell function particularly in regulating the intensity and duration of immune responses.
The PD-1 pathway plays an important role in cancer and autoimmune diseases. Tumors often exploit the PD-1 pathway to evade immune surveillance leading to cancer progression. In such cases blocking PD-1 with inhibitors like anti-PD-1 antibodies (e.g. EH12.2H7 and chimeric antibodies) can re-activate T cells against cancer cells. Conversely in autoimmune diseases heightened PD-1 expression or activity could help in moderating aberrant immune responses where the immune system attacks the body's own tissues. The PD-1 pathway interacting with proteins such as CTLA-4 in cancer and autoimmune contexts represents a target for therapeutics aiming to modulate the immune system to improve disease outcomes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Cells were fixed with 100?l 4% PFA for 10 min at RT, then permeabilized with 100?l 90% methanol for 30 min (-20° C) followed by blocking with 10% goat serum for 1h at room temperature. Incubate ab52587 for 30 min at room temperature (RT) and then incubate Goat anti-Mouse IgG (Alexa Fluor® 488, Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) ab150113) for 30 min at room temperature. Positive staining on MOLT-4 treated with 10ng/ml PMA and 500ng/ml Ionomycin for 24h, but weak staining on untreated MOLT-4.
Immunohistochemical analysis of permeabilized frozen Human tonsil tissue labeling PD1 with Anti-Agrin antibody [EPR28044-74] ab316965 at 1/10000 dilution, followed by LeicaDS9800 (Bond™ PolymerRefine Detection). Counterstained with hematoxylin. The immunostaining was performed on a Leica Biosystems BOND® RX instrument.
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized MOLT-4 cells labelling PD1 with ab52587 at 1/100 dilution, followed by Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) preadsorbed (Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) preadsorbed ab150117) at 1/1000 dilution at RT for 45 min. Recombinant Alexa Fluor® 594 Anti-beta Tubulin antibody [EPR16774] (Alexa Fluor® 594 Anti-beta Tubulin antibody [EPR16774] ab206369) was used as a counterstain at 1/50 dilution and was co-incubated with ab52587 overnight at 4° C. Nucleus were visualized using DAPI. Confocal image showing membranous staining in MOLT-4 cells treated with 500 ng/ml Ionomycin and 10 ng/ml Phorbol-12-myristate-13-acetate (PMA) for 24 hours, and no staining in MOLT-4 cells.
Immunohistochemical analysis of permeabilized frozen Human cardiac muslce tissue labeling PD1 with Anti-Agrin antibody [EPR28044-74] ab316965 at 1/10000 dilution, followed by LeicaDS9800 (Bond™ PolymerRefine Detection). No staining on human cardiac muscle. Counterstained with hematoxylin. The immunostaining was performed on a Leica Biosystems BOND® RX instrument.
Immunohistochemical analysis of paraffin-embedded Human tonsil tissue labeling PD1 with ab52587 at 1/100 dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection). The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin. Heat mediated antigen retrieval was performed with Citrate buffer (pH 6.0, Epitope Retrieval Solution 1) for 20 mins.
Immunohistochemical analysis of paraffin-embedded Human cardiac muscle tissue labeling PD1 with ab52587 at 1/100 dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection). No staining on human cardiac muscle. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin. Heat mediated antigen retrieval was performed with Citrate buffer (pH 6.0, Epitope Retrieval Solution 1) for 20 mins.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Lane 1: Untreated MOLT-4 (human lymphoblastic leukemia T lymphoblast) whole cell lysate at 20 µg
Lane 2: MOLT-4 treated with 500ng/ml Ionomycin and 10ng/ml Phorbol-12-myristate-13-acetate (PMA) for 24 hours, whole cell lysate at 20 µg
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com